144 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
10 May 24
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
7:01am
are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking
424B3
KPRX
Kiora Pharmaceuticals Inc
28 Mar 24
Prospectus supplement
4:48pm
and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Mar 24
Results of Operations and Financial Condition
7:03am
of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, Kiora's
8-K
EX-99.1
b7od43 kmg
12 Feb 24
Regulation FD Disclosure
5:23pm
8-K
EX-10.2
urulq7cwdc
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-10.1
9va28r7 suel03l20z1t
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-99.1
fu3qz4okl0d
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-10.1
bdp3ddzyl
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.2
gfr dbszj29br3ce2rzl
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
r0zlebmmyfg
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
5im9t9
9 Nov 23
Regulation FD Disclosure
7:02am
8-K
EX-99.1
wkz1wk jcbli
9 Nov 23
Results of Operations and Financial Condition
7:01am
8-K
EX-99.1
sosb8hfmu 29m3b
6 Nov 23
Topline Phase I/II First-in-Human Results Presented at AAO 2023
6:05am
8-K
EX-99.1
5odpy8aek0tk4ewbnb
21 Sep 23
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
7:00am
DEFA14A
EX-99.1
ct2n p9g8h4qvm
1 Sep 23
Additional proxy soliciting materials
7:00am